20 completed, 2 terminated, 1 withdrawn. 17 Phase 1, 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 16, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow AT-511: new trials by email Literature Review of AT-511 trials Research Report on AT-511
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination - Healthy Volunteer Study, Hepatic Impairment | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 28 | 2025-04-09 | 2026-07-31 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 38 | 2025-04-08 | 2025-08-29 |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| The Study of Bemnifosbuvir in Healthy Japanese Subjects Bemnifosbuvir (BEM) - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 14 | 2023-04-26 | 2023-06-15 |
| Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects Bemnifosbuvir (BEM), Placebo, Moxifloxacin - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 35 | 2023-04-25 | 2023-06-15 |
| Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir Cohort 1 BEM + Ruzasvir, Cohort 2 Ruzasvir + BEM - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 32 | 2023-01-30 | 2023-06-01 |
| Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function Bemnifosbuvir (BEM) - Healthy Volunteer, Hepatic Impairment | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 39 | 2023-01-30 | 2024-07-31 |
| SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 Bemnifosbuvir (BEM), Placebo - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19 | Phase 3 | Completed | Atea Pharmaceuticals, Inc. | 2285 | 2022-11-25 | 2025-06-13 |
| Study of AT-527 in Subjects With Normal and Impaired Renal Function AT-527, AT-527 and Probenecid - Healthy Volunteer, Renal Impairment | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 36 | 2022-10-17 | 2024-07-31 |
| Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal AT-527 fasted, Placebo Comparator fasted, AT-527 fed - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 136 | 2022-02-22 | 2022-10-18 |
| Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) Drug: AT-527 + rosuvastatin, AT-527 + rosuvastatin - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 29 | 2021-11-16 | 2022-02-25 |
| Drug-drug Interaction Study of Digoxin and AT-527 (R07496998) AT-527 + digoxin - Healthy Volunteers Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 29 | 2021-11-03 | 2022-02-28 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic | Phase 1 / Phase 2 | Withdrawn | Atea Pharmaceuticals, Inc. | 2021-10-01 | 2022-06-08 | |
| Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998) AT-527 (R07496998) - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 6 | 2021-07-28 | 2022-02-25 |
| Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 RO7496998, Placebo - COVID-19 | Phase 3 | Terminated | Hoffmann-La Roche | 216 | 2021-04-28 | 2024-01-05 |
| Bronchopulmonary PK of AT-527 (R07496998) AT-527 - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 24 | 2021-04-25 | 2022-02-25 |
| Drug-drug Interaction Study of Midazolam and AT-527 (R07496998) AT-527 550 mg + midazolam - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 24 | 2021-04-22 | 2021-07-29 |
| Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998) AT-527 550 mg + cyclosporine - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 24 | 2021-04-18 | 2021-08-02 |
| Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527 Period 1: AT-527 550 mg, Period 2: carbamazepine, Period 3: AT-527 550 mg + carbamazepine - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 20 | 2021-03-01 | 2021-07-29 |
| Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19 AT-527, Placebo - COVID-19 | Phase 2 | Completed | Hoffmann-La Roche | 104 | 2021-02-03 | 2022-10-26 |
Showing 20 of 23. Sign in to see all of them.
COVID-19 (4) · Hepatitis C (4) · Hepatitis C, Chronic (4) · Renal Insufficiency (2) · Flaviviridae Infections (1) · Hepatitis, Viral, Human (1) · Liver Cirrhosis (1) · Liver Diseases (1)
Atea Pharmaceuticals, Inc. (21) · Hoffmann-La Roche (2)
Canada (13) · United States (7) · Belgium (5) · Brazil (4) · Moldova (4) · Romania (4) · Argentina (3) · South Africa (3) · Spain (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Germany (2) · India (2) · Japan (2) · Latvia (2)
Xiao-Jian Zhou, PhD (2) · Xiao-Jian Zhou (1)
PMID 31570394, PMID 37338393, PMID 37928891, PMID 38051993
2019 (2)